A living WHO guideline on drugs for COVID-19
BMJ
; 370: [1-14], Sept. 04, 2020.
Article
in English
| BIGG - GRADE guidelines
| ID: biblio-1129878
Responsible library:
BR1.1
ABSTRACT
What is the role of drug interventions in the treatment of patients with covid-19? The latest version of this WHO living guidance focuses on remdesivir, following the 15 October 2020 preprint publication of results from the WHO SOLIDARITY trial. It contains a weak or conditional recommendation against the use of remdesivir in hospitalised patients with covid-19 The first version on this living guidance focused on corticosteroids. The strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19 are unchanged.
Full text:
Available
Collection:
Tematic databases
Database:
BIGG - GRADE guidelines
Main subject:
Adrenal Cortex Hormones
/
Anti-Retroviral Agents
/
COVID-19
Type of study:
Practice guideline
Language:
English
Journal:
BMJ
Year:
2020
Document type:
Article